Search PubMed⌕ Search

Biomedical subjects

A M Cooperman

Publications and source records attributed to A M Cooperman.

At least 55 records · Page 3Linked to original sources

Cancer of the pancreas: a dilemma in treatment.

The debate about what operation to perform for pancreatic cancer will, it is hoped, soon be ended. Individual philosophies will continue to dominate reason, but whatever one's philosophy or favorite operation, a critical look at surgeon's morbidity and mortality versus his or her patients' survival must dictate what will be done. The most optimistic five-year survival rate dose not exceed 5 per cent, and I believe the mortality must be lower than this. I suspect that disappointments with total pancreatectomy and more drastic operations will continue to be registered. As is the case with many neoplasms that, unfortunately, tend to be systemic, local measures are futile. Progress will be made by looking for better ways to extirpate these lesions and by an understanding of why there is an increase in pancreatic cancer.

Biopsy↗

Bleeding esophageal varices.

The unresolved issue of the optimal treatment of portal hypertension attests to the disappointments in present treatment. In reality, the disappointments are a result of progressive liver disease, which is not helped and probably deteriorates more rapidly after shunting operations. This dissatisfaction has led some to abandon shunts and to accept a higher incidence or potential for recurrent bleeding after nonshunting operations. The long-term results of splenic artery ligation and perhaps embolization are awaited with interest. Until then, as Conn has said, "We must learn to select better who should be shunted or to shunt better those we select".

Embolization, Therapeutic↗

Postgastrectomy syndromes.

The preceding briefly summarizes some mechanical, metabolic, and motility disturbances that develop after gastric operations. Clearly, the more thorough the search and questions, the greater the incidence of minor, moderate, or severe impairment by one or more of these disorders. Our previous fears in treating benign ulcer disease were, first, mortality and, then, recurrent ulcers. Postgastrectomy syndromes were thought of secondarily. The seriousness, frequency, and lack of specific treatment available for most postgastrectomy syndromes were generally not recognized. While serious sequelae are infrequent, some take years to develop. A few, such as cancer, are regrettable even if treatable. Surgical correction of most of these syndromes is at best 50 to 80 percent effective. Poor selection of patients, mixed symptoms, and our inability to repiece vagus nerves and excised antrums make it difficult, if not impossible, to correct totally the anatomic and physiologic changes. Surgical intervention is infrequent. For some abnormalities, such as bile reflux gastritis, correction is uniformly good if gastric emptying is satisfactory and the syndrome exists alone. For others, such as dumping and diarrhea, treatment is less exacting, and the variety of operative alternatives often confuses rather than helps. My own continually changing experiences have taught me to correct the major disability in the simplest way. My experience with take-down of gastrojejunostomies and pyloroplasties is limited but encouraging. My satisfaction with Roux-en-Y conversions of Billroth II resections in reflux gastritis has been extended to the correction of diarrhea and dumping. Creating a long isoperistaltic limb between stomach and jejunum has provided surprisingly excellent relief for the problems of rapid emptying, although I have not objectively verified emptying changes in all successfully treated patients. The best results come with avoidance of these disorders. It is hoped that simpler operations for ulcer disease will continue to gain in popularity. Highly selective vagotomy is an easier, more attractive alternative than any of the aforementioned remedial procedures, particularly if the long-term results are good.

Afferent Loop Syndrome↗

Pancreatoduodenal resection and total pnacreatectomy--an institutional review.

Between 1940 and 1978, 150 major pancreatic resections--92 pancreatoduodenal resections (PDRs) and 58 total pancreatectomies (TPs)--were performed for benign and malignant disease. The majority of resections were for pancreatic cancer (70 patients) and ampullary cancer (40 patients). The overall operative mortality rate for PDR was 14%; it was 26% for TP. After resection for adenocarcinoma of the head of the pancreas, the operative mortality rate was 28% for TP and 15% for PDR. The number of 5-year survivors after resection for cancer of the head of the pancreas was four (5.7%). Three survived after PDR and one after TP. Of the 42 adenocarcinomas resected by TP, one of the patients had multicentric cancer and two others had carcinoma in situ. TP appears to have no advantage over PDR for cancers of the head of the pancreas from a theoretical or practical standpoint.

Adenocarcinoma↗

Failure of LeVeen shunting in refractory ascites--a view from the other side.

We have reviewed our experience with 11 patients treated with LeVeen peritoneovenous shunts during a 22-month period from March, 1976, through December, 1977, to assess long-term results and shunt patency. Nine patients had follow-up studies to assess shunt patency at a mean of 26 months. After insertion of the shunt, the mean weight loss was 7.9 kg at hospital discharge. At 26-month follow-up evaluation, six patients had minimal ascites (responders), whereas five had massive ascites (nonresponders). Of the six responders, three patients with nonfunctioning shunts lost an average of 15.8 kg of ascites, three whereas with patent shunts lost an average of 15.0 kg. Eight of 11 patients (73%) required revision or replacement of the shunt because of malfunction; clotting was the most common cause of failure. We conclude that the role and effectiveness of LeVeen peritoneovenous shunts remain questionable. They may cause diuresis, maintain it, or not be responsible for it all. Clinical reports that cite their effectiveness should document patency of these shunts.

Adult↗

Portal hypertension associated with systemic mastocytosis and splenomegaly.

An unusual case of systemic mastocytosis with splenomegaly, portal hypertension, and bleeding esophageal varices is presented. Arteriograms and liver biopsy suggested the mechanism of the portal hypertension was due to increased blood flow in the splenic vein, although splenic arteriovenous shunting secondary to histamine release and increased intrahepatic resistance secondary to mast cell infiltration might have played a role. The portal hypertension was relieved by splenectomy.

Esophageal and Gastric Varices↗

Endoscopic retrograde pancreatography in the evaluation of trauma to the pancreas.

Pancreatic injury is an unusual but serious complication of abdominal trauma. A high index of suspicion is required, as results of routine laboratory tests and physical examination can be misleading. Complications following injury to the body and tail may be particularly indolent in their presentation. Endoscopic retrograde pancreatography allows accurate localization of the site of pancreatic duct disruption and facilitates appropriate surgical management.

Abdominal Injuries↗

A simplified method and approach to the distal splenorenal shunt.

Several procedures have been developed to obtain decompression of protal hypertension for bleeding esophageal varices. In recent years, the distal splenorenal shunt has become popular becuase it causes less encephalopathy than the standard portacaval or mesocaval shunts. A criticism of the distal splenorenal shunt has been the technical difficulty of dissecting the splenic vein and obtaining adequate exposure. We have facilitated some of these difficulties by exposing a retroperitoneal approach and by the use of a Smith ring retractor.

Humans↗

Nucleation time: a key factor in the pathogenesis of cholesterol gallstone disease.

In earlier studies, we concluded that biliary cholesterol supersaturation may be a necessary but not sufficient cause for gallstone formation. In the present studies, we calculated cholesterol saturation indices (CSI) for 120 bile specimens of cholesterol gallstone patients and controls, using the solubility boundaries of Carey and Small (J Clin Invest 61:998-1026, 1978) for artificial biles. The mean CSI + SD was 1.42 +/- 0.68 for controls and 1.80 +/- 1.02 for cholesterol gallstone patients. Of the control bile samples, 68% were supersaturated. Since the two groups could not be sharply distinguished by saturation index, we studied another property of bile samples: nucleation time for cholesterol crystal formation. The mean nucleation time for 16 control bile samples was 15 days, and a strong correlation (r = 0.84) was found between CSI and nucleation time. Twelve bile samples of cholesterol gallstone patients had a mean nucleation time of 3 days and no correlation between CSI and nucleation time. A discriminant analysis of the data, which took into account both the CSI and the nucleation time for each sample, allowed a sharp distinction between bile samples of cholesterol gallstone patients and controls. This distinction could not have been drawn from studies with artificial biles, since these differ only in their CSI.

Bile↗